Bristol Myers Squibb and Johnson & Johnson have said they will stop development of their oral Factor XIa inhibitor milvexian in acute coronary syndrome after a disappointing trial result. The decision ...

Bristol Myers Squibb and Pfizer have launched an online programme to sell their blockbuster anticoagulant Eliquis directly to patients, following in the footsteps of Eli Lilly and Novo Nordisk in a ...

The impending merger between Bristol-Myers Squibb (BMS) and Medarex marks the end of an era. Medarex is one of the last independent public biotech companies that built their businesses around ...